13G Filing: James E. Flynn and Audentes Therapeutics Inc (BOLD)

Page 12 of 18

Page 12 of 18 – SEC Filing

CUSIP No. 05070R104 13G Page 12 of
15
(iii)

Sole power to dispose or to direct the disposition of

All Reporting Persons – 0
(iv)

Shared power to dispose or to direct the disposition
of

Deerfield Mgmt, L.P. – 1,214,423

Deerfield Mgmt III, L.P.
– 889,230

Deerfield Management Company, L.P. – 2,103,653

Deerfield Special Situations Fund, L.P. – 514,423

Deerfield Partners,
L.P. – 308,000

Deerfield International Master Fund, L.P. – 392,000

Deerfield Private Design Fund III, L.P. –
889,230

James E. Flynn – 2,103,653

**See footnotes on cover pages which are incorporated by reference herein.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities check the following ☐.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds
from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest
relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment
company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or
endowment fund is not required.

N/A
Item 7.

Identification and Classification of the Subsidiary
Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under
Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent
holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating
the identification of the relevant subsidiary.

N/A
Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit
stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to
ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

See Exhibit B
Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings
with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual
capacity. See Item 5.

N/A

Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)

Page 12 of 18